Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydralazine + valproic acid
- Development stage
- Phase 2
- Lead developer
- Instituto Nacional de Cancerologia de Mexico
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Hydralazine + valproic acid** is an investigational oral epigenetic anticancer combination administered as two separate small-molecule drugs. Hydralazine has been studied as a DNA hypomethylating agent, while valproic acid inhibits histone deacetylases. Together, the regimen is intended to reverse epigenetic silencing of tumor-suppressor, antigen-presentation, and other growth-regulatory genes, potentially enhancing tumor immunogenicity and sensitivity to chemotherapy and radiotherapy. The combination has been evaluated in cervical cancer, breast cancer, advanced hepatocellular carcinoma, myelodysplastic syndromes, refractory solid tumors, and advanced previously treated solid tumors. It is not an approved fixed-dose combination product.
- Brand names
- Transkrip
- Other names
- HVhydralazine + valproatehydralazine and valproatehydralazine and valproic acid
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)HDAC (HDAC family)
Beyond the preview
Go deeper on hydralazine + valproic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydralazine + valproic acid.